# Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects

> **NCT05256017** · PHASE2,PHASE3 · COMPLETED · sponsor: **Drugs for Neglected Diseases** · enrollment: 1208 (actual)

## Conditions studied

- Trypanosomiasis, African
- Trypanosoma Brucei Gambiense; Infection
- Sleeping Sickness

## Interventions

- **DRUG:** Acoziborole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05256017
- **Lead sponsor:** Drugs for Neglected Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-30
- **Primary completion:** 2023-08-03
- **Final completion:** 2023-08-03
- **Target enrollment:** 1208 (ACTUAL)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05256017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05256017, "Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05256017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*